← Leaderboards
Hallgeir Rui
Henry M. Jackson Fdn For The Adv Mil/Med
$8,795,002
Attributed
$9,913,272
Total exposure
11
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $951.7K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,913,272 · 11
By mechanism
R01$8,859,759 · 6
R21$785,042 · 2
R03$169,998 · 1
P30$94,472 · 1
R13$4,001 · 1
Top collaborators
- Inna Chervoneva3 shared
- Lubna N. Chaudhary2 shared
- Dev Karan2 shared
Others in their field
Top investigators on “Prolactin”
- Susan E. Hankinson · University Of Massachusetts Amherst$28,528,655
- Thomas Scott Stroup · University Of North Carolina Chapel Hill$10,682,303
- Charles V Clevenger · University Of Pennsylvania$7,339,531
- Sally A. Camper · University Of Michigan At Ann Arbor$6,828,197
- Betsy Lozoff · University Of Michigan At Ann Arbor$6,129,416
- Nira Ben-Jonathan · University Of Cincinnati$5,889,779
Research focus
ProlactinTumorMalignant Breast NeoplasmHormonesEndocrineProteinsSignal TransductionMalignant NeoplasmsPre-ClinicalPathway InteractionsResponseInsightMolecularIn VivoNeoplasm MetastasisBreast Cancer DiagnosisPre-Clinical ModelClinical TrialsBreast Cancer ModelProlactin ReceptorCell LineExpectationPhysiologicalBase
Grant awards (43)
WNT pathway-driven anti-estrogen therapy resistance in breast cancer$549,696
R01 · FY2025 · CA · contact PI
WNT pathway-driven anti-estrogen therapy resistance in breast cancer$537,544
R01 · FY2024 · CA · contact PI
Novel chemokine in the regulation of breast cancer metastasis$407,391
R21 · FY2024 · CA
Novel chemokine in the regulation of breast cancer metastasis$6,813
R21 · FY2024 · CA
WNT pathway-driven anti-estrogen therapy resistance in breast cancer$565,098
R01 · FY2023 · CA · contact PI
Quantitative Analyses of HER2 Upregulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine Therapy$81,220
R03 · FY2022 · CA
Quantitative Analyses of HER2 Upregulation in Luminal Breast Cancer in Response to Neoadjuvant Endocrine Therapy$88,778
R03 · FY2021 · CA
Prolactin pathways and metastatic progression of ER-positive breast cancer$338,844
R01 · FY2019 · CA · contact PI
Prolactin pathways and metastatic progression of ER-positive breast cancer$349,457
R01 · FY2018 · CA · contact PI
Prolactin pathways and metastatic progression of ER-positive breast cancer$349,586
R01 · FY2017 · CA · contact PI
Prolactin pathways and metastatic progression of ER-positive breast cancer$362,925
R01 · FY2016 · CA · contact PI
Prolactin pathways and metastatic progression of ER-positive breast cancer$373,133
R01 · FY2015 · CA · contact PI
Molecular features of patient-derived luminal breast cancer xenotransplant models$166,388
R21 · FY2015 · CA · contact PI
Molecular features of patient-derived luminal breast cancer xenotransplant models$2,175
R21 · FY2015 · CA · contact PI
Molecular features of patient-derived luminal breast cancer xenotransplant models$202,275
R21 · FY2014 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$313,385
R01 · FY2012 · CA · contact PI
Endocrine Mechanisms and Hormone Action in Cancer$30,359
P30 · FY2012 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$313,385
R01 · FY2011 · CA · contact PI
Endocrine Mechanisms and Hormone Action in Cancer$31,130
P30 · FY2011 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$323,078
R01 · FY2010 · CA · contact PI
Endocrine Mechanisms and Hormone Action in Cancer$32,983
P30 · FY2010 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$323,078
R01 · FY2009 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$148,739
R01 · FY2009 · CA · contact PI
Experimental Modeling of Human Breast Cancer in Mice$337,014
R01 · FY2008 · CA · contact PI
Stat5 as a gatekeeper in human breast cancer metastasis$239,847
R01 · FY2008 · CA · contact PI
Prolactin and Growth Hormone Family 2008 Gordon Research Conference$1
R13 · FY2008 · DK · contact PI
Stat5 as a gatekeeper in human breast cancer metastasis$239,847
R01 · FY2007 · CA · contact PI
Prolactin and Growth Hormone Family 2008 Gordon Research Conference$4,000
R13 · FY2007 · DK · contact PI
Stat5 as a gatekeeper in human breast cancer metastasis$246,889
R01 · FY2006 · CA · contact PI
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$325,258
R01 · FY2005 · CA
Stat5 as a gatekeeper in human breast cancer metastasis$223,386
R01 · FY2005 · CA
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$17,169
R01 · FY2005 · CA
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$339,958
R01 · FY2004 · CA
Stat5 as a gatekeeper in human breast cancer metastasis$234,702
R01 · FY2004 · CA
Prolactin Induced Phosphoprotein Signal Transduction$232,800
R01 · FY2004 · DK
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$337,560
R01 · FY2003 · CA
Prolactin Induced Phosphoprotein Signal Transduction$232,340
R01 · FY2003 · DK
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$313,113
R01 · FY2002 · CA
Prolactin Induced Phosphoprotein Signal Transduction$232,800
R01 · FY2002 · DK
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$20,112
R01 · FY2002 · CA
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$246,012
R01 · FY2001 · CA
TARGETING OF TYROSINE KINASE PATHWAYS IN PROSTATE CANCER$18,525
R01 · FY2001 · CA
PROLACTIN INDUCED PHOSPHOPROTEIN SIGNAL TRANSDUCTION$174,479
R01 · FY2000 · DK